Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

[1]  M. Fleseriu,et al.  Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study , 2014, The Journal of clinical endocrinology and metabolism.

[2]  S. Mudaliar,et al.  Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. , 2013, The Journal of clinical endocrinology and metabolism.

[3]  S. Ezzat,et al.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: executive summary. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  A. Colao,et al.  Resistance to somatostatin analogs in acromegaly. , 2011, Endocrine reviews.

[5]  S. Melmed,et al.  Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  A. Colao,et al.  Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. , 2009, The Journal of clinical endocrinology and metabolism.

[7]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  G. Gamble,et al.  A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. , 2008, European journal of endocrinology.

[9]  M. Sheppard,et al.  Does acromegaly enhance mortality? , 2008, Reviews in Endocrine and Metabolic Disorders.

[10]  P. Caron,et al.  Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa , 2007, Clinical endocrinology.

[11]  P. Cappabianca,et al.  First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group , 2006, Journal of endocrinological investigation.

[12]  G. Lasio,et al.  Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. , 2006, The Journal of clinical endocrinology and metabolism.

[13]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[14]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[16]  P. Stewart,et al.  Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  G. Meno-Tetang,et al.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. , 2002, European journal of endocrinology.

[18]  F. Di Salle,et al.  Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly , 2002, Clinical endocrinology.

[19]  P. Cappabianca,et al.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. , 2001, The Journal of clinical endocrinology and metabolism.

[20]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[21]  M. Thangaraju,et al.  Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. , 1999, Diabetes.